Press Releases Keyword Search Year None2019201820172016201520142013 12/02/19 Avadel Pharmaceuticals Announces Key Appointments to Leadership Team To Support Continued Transformation and the Advancement of FT218 - - - Thomas S. McHugh appointed as Chief Financial Officer - - - Dr. Jason Vaughn appointed Senior ... 11/25/19 Avadel Pharmaceuticals Achieves Enrollment Target in REST-ON Phase 3 Pivotal Trial of FT218 for Excessive Daytime Sleepiness and Cataplexy in Patients with Narcolepsy 205 patients enrolled; additional patients currently in screening will be allowed to enroll if eligi... 11/21/19 Avadel Pharmaceuticals to Present at Two Upcoming Investor Conferences DUBLIN, Ireland , Nov. 21, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a com... 11/12/19 Avadel Pharmaceuticals Reports Third Quarter 2019 Financial Results and Raises Revenue Guidance for FY2019 Enrollment currently at 200 patients for the pivotal REST-ON Phase 3 study (97.5% complete); the Com... 10/29/19 Avadel Pharmaceuticals to Report Third Quarter 2019 Financial Results on November 12th DUBLIN, Ireland , Oct. 29, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a com... 10/04/19 Avadel Announces Resignation of Kevin Kotler from Board of Directors DUBLIN, Ireland , Oct. 04, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a com... 09/24/19 Avadel Pharmaceuticals Announces Pharmacokinetic (PK) Data for Once-Nightly FT218 that will be Included in an Oral Presentation at the World Sleep 2019 Congress on September 25th DUBLIN, Ireland , Sept. 24, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a co... 09/23/19 Avadel Pharmaceuticals Announces FDA Agreement to Reduce the Sample Size for the Ongoing Pivotal Phase 3 Study for Once-Nightly FT218; Full Enrollment Now Expected by End of 2019 FDA agrees with Company’s proposed changes to the statistical analysis plan for the REST-ON Phase ... 09/18/19 Avadel Pharmaceuticals Announces an Oral Presentation on Investigational Once-Nightly Sodium Oxybate (FT218) at the World Sleep 2019 Congress on September 25th DUBLIN, Ireland , Sept. 18, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a co... 09/17/19 Avadel Pharmaceuticals to Present at the Ladenburg Thalmann 2019 Healthcare Conference on September 24th DUBLIN, Ireland , Sept. 17, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a co... 08/09/19 Avadel Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Company Update Better-than-expected Hospital Product revenue improves liquidity position Restructuring and other co... 08/08/19 Avadel Pharmaceuticals Receives New PDUFA Date for AV001 of December 15, 2019 PDUFA Action Extended 3 Months; Launch Remains on Track for 1Q 2020 DUBLIN, Ireland , Aug. 08, 2019 ... 08/01/19 Avadel Pharmaceuticals Further Strengthens Clinical and Medical Team Appoints Courtney Wells as Vice President, Clinical Operations; and David Seiden, M.D., as Senior Me... 07/29/19 Avadel Pharmaceuticals to Report Second Quarter 2019 Financial Results DUBLIN, Ireland , July 29, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a com... 06/04/19 Avadel to Present New Data on Once-Nightly Sodium Oxybate at SLEEP 2019 Conference DUBLIN, Ireland , June 04, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a com... 06/03/19 Avadel Pharmaceuticals Appoints Gregory J. Divis Chief Executive Officer DUBLIN, Ireland , June 03, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a com... 05/22/19 Avadel Pharmaceuticals Announces FDA Acceptance of New Drug Application for AV001 AV001 granted Priority Review PDUFA action date is September 15, 2019 DUBLIN, Ireland , May 22, 2019... 05/08/19 Avadel Pharmaceuticals Reports First Quarter 2019 Financial Results REST-ON 63% enrolled; 98 patients remain to be enrolled Jordon Dubow , M.D., appointed as Chief Me... 04/29/19 Avadel Pharmaceuticals Announces Appointment of Jordan Dubow, M.D., as Chief Medical Officer DUBLIN, Ireland , April 29, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a co... 04/29/19 Avadel Pharmaceuticals to Report First Quarter 2019 Financial Results DUBLIN, Ireland , April 29, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a co... 03/15/19 Avadel Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results DUBLIN, Ireland , March 15, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a co... 03/07/19 Avadel Pharmaceuticals to Report Fourth Quarter and Full Year 2018 Financial Results DUBLIN, Ireland , March 07, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a co... 02/07/19 Avadel Pharmaceuticals Clarifies Announcement of Corporate Restructuring DUBLIN, Ireland , Feb. 07, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL) provid... 02/07/19 Avadel Pharmaceuticals Announces Restructuring to Focus on FT218 Clinical Development Program - Company cost structure expected to be reduced by $70 to $75 million in 2019 – - Approximately $100... 01/23/19 ‘Sleep Normal’ campaign urges Americans to end frequent nighttime urination and stop settling for nights of bad sleep Nearly 50 million Americans wake up to urinate more than once per night due to a treatable medical c... 01/03/19 Avadel Pharmaceuticals Announces Changes to Management Team and Board of Directors - Michael S. Anderson resigns as Chief Executive Officer and member of Avadel’s Board of Directors –...
12/02/19 Avadel Pharmaceuticals Announces Key Appointments to Leadership Team To Support Continued Transformation and the Advancement of FT218 - - - Thomas S. McHugh appointed as Chief Financial Officer - - - Dr. Jason Vaughn appointed Senior ...
11/25/19 Avadel Pharmaceuticals Achieves Enrollment Target in REST-ON Phase 3 Pivotal Trial of FT218 for Excessive Daytime Sleepiness and Cataplexy in Patients with Narcolepsy 205 patients enrolled; additional patients currently in screening will be allowed to enroll if eligi...
11/21/19 Avadel Pharmaceuticals to Present at Two Upcoming Investor Conferences DUBLIN, Ireland , Nov. 21, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a com...
11/12/19 Avadel Pharmaceuticals Reports Third Quarter 2019 Financial Results and Raises Revenue Guidance for FY2019 Enrollment currently at 200 patients for the pivotal REST-ON Phase 3 study (97.5% complete); the Com...
10/29/19 Avadel Pharmaceuticals to Report Third Quarter 2019 Financial Results on November 12th DUBLIN, Ireland , Oct. 29, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a com...
10/04/19 Avadel Announces Resignation of Kevin Kotler from Board of Directors DUBLIN, Ireland , Oct. 04, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a com...
09/24/19 Avadel Pharmaceuticals Announces Pharmacokinetic (PK) Data for Once-Nightly FT218 that will be Included in an Oral Presentation at the World Sleep 2019 Congress on September 25th DUBLIN, Ireland , Sept. 24, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a co...
09/23/19 Avadel Pharmaceuticals Announces FDA Agreement to Reduce the Sample Size for the Ongoing Pivotal Phase 3 Study for Once-Nightly FT218; Full Enrollment Now Expected by End of 2019 FDA agrees with Company’s proposed changes to the statistical analysis plan for the REST-ON Phase ...
09/18/19 Avadel Pharmaceuticals Announces an Oral Presentation on Investigational Once-Nightly Sodium Oxybate (FT218) at the World Sleep 2019 Congress on September 25th DUBLIN, Ireland , Sept. 18, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a co...
09/17/19 Avadel Pharmaceuticals to Present at the Ladenburg Thalmann 2019 Healthcare Conference on September 24th DUBLIN, Ireland , Sept. 17, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a co...
08/09/19 Avadel Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Company Update Better-than-expected Hospital Product revenue improves liquidity position Restructuring and other co...
08/08/19 Avadel Pharmaceuticals Receives New PDUFA Date for AV001 of December 15, 2019 PDUFA Action Extended 3 Months; Launch Remains on Track for 1Q 2020 DUBLIN, Ireland , Aug. 08, 2019 ...
08/01/19 Avadel Pharmaceuticals Further Strengthens Clinical and Medical Team Appoints Courtney Wells as Vice President, Clinical Operations; and David Seiden, M.D., as Senior Me...
07/29/19 Avadel Pharmaceuticals to Report Second Quarter 2019 Financial Results DUBLIN, Ireland , July 29, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a com...
06/04/19 Avadel to Present New Data on Once-Nightly Sodium Oxybate at SLEEP 2019 Conference DUBLIN, Ireland , June 04, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a com...
06/03/19 Avadel Pharmaceuticals Appoints Gregory J. Divis Chief Executive Officer DUBLIN, Ireland , June 03, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a com...
05/22/19 Avadel Pharmaceuticals Announces FDA Acceptance of New Drug Application for AV001 AV001 granted Priority Review PDUFA action date is September 15, 2019 DUBLIN, Ireland , May 22, 2019...
05/08/19 Avadel Pharmaceuticals Reports First Quarter 2019 Financial Results REST-ON 63% enrolled; 98 patients remain to be enrolled Jordon Dubow , M.D., appointed as Chief Me...
04/29/19 Avadel Pharmaceuticals Announces Appointment of Jordan Dubow, M.D., as Chief Medical Officer DUBLIN, Ireland , April 29, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a co...
04/29/19 Avadel Pharmaceuticals to Report First Quarter 2019 Financial Results DUBLIN, Ireland , April 29, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a co...
03/15/19 Avadel Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results DUBLIN, Ireland , March 15, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a co...
03/07/19 Avadel Pharmaceuticals to Report Fourth Quarter and Full Year 2018 Financial Results DUBLIN, Ireland , March 07, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a co...
02/07/19 Avadel Pharmaceuticals Clarifies Announcement of Corporate Restructuring DUBLIN, Ireland , Feb. 07, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL) provid...
02/07/19 Avadel Pharmaceuticals Announces Restructuring to Focus on FT218 Clinical Development Program - Company cost structure expected to be reduced by $70 to $75 million in 2019 – - Approximately $100...
01/23/19 ‘Sleep Normal’ campaign urges Americans to end frequent nighttime urination and stop settling for nights of bad sleep Nearly 50 million Americans wake up to urinate more than once per night due to a treatable medical c...
01/03/19 Avadel Pharmaceuticals Announces Changes to Management Team and Board of Directors - Michael S. Anderson resigns as Chief Executive Officer and member of Avadel’s Board of Directors –...
